Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tariq Sadeq has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Healing Power Of Dietary Supplements To Prevent Long-Term Covid-19; A Prospective Observation Study

    by Hadi Mohammad, Tariq Sadeq, Media Ismail, Swar O Ahmed, Zana Ameen

    The novel coronavirus which emerged from Wuhan, China, in December 2019, was first described as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and affects different systems in the body resulting in different symptoms and severity. The role of macro and micro nutrients plus gut microbiome (gut-lung axis) to boost the immune system is well documented. Therefore, this study aims to boost the immune system particularly the lung immunity to shorten the infection course and prevent post-covid complications. The study strategy depends on maintaining the maximum nutritional status for well-functioning immune system, directing immune system to focus on viral infection by minimizing all the other oxidative stress pathways that cause further damage and put the body immune system under pressure. Furthermore, this study exploits all the possible mechanisms that could promote lung immunity via boosting healthy microbiome. This study includes 183 patients with positive PCR test and typical COVID-19 symptoms from Feb 2020 to Jun 2022. The patients were guided to follow a designed protocol which includes food supplements and healthy diet and nutrition. After 3 days of the protocol initiation, the covid score reduced by 1.14 (p


  • Open Access

    Development of Polymeric Nanoparticles of Sunitinib malate in Eudragit S 100 for anti-colon cancer targeted drug delivery

    by Shahid Jamil, Khalid Anwer, Tariq Sadeq, Kanchan Kohli

    Sunitinib malate (SM) is a multi-targeted tyrosine kinase (TK) inhibitor. It is proposed as a potent anticancer drug intended for colon cancer. The current work aimed at developing Sunitinib malate -loaded nanoparticles for colon- targeting. SM loaded ES100-nanoparticles were developed by nano-precipitation method using poly vinyl alcohol (PVA) as stabilizer. Different formulation of ESNP (F1-F3) were prepared and evaluated for particle size, poly-dispersity index, and drug entrapment, using Fourier transform infrared spectroscopy (FTIR), x-ray diffraction (XRD), and scanning electron microscopy (SEM). The optimized formulation was further studied by in-vitro drug release and anticancer cell line study. The mean particle size, PDI, %EE of optimized SM loaded ESNPF2 was found to be 384.8±5.53 nm, 0.58, and 60.31% respectively. In vitro release of the optimized ESNPF2 showed 10.2 % drug release till 2 h, at 4h 29.6% and 12 h and 24 h 66.45%, 82.2% respectively at pH 7.4. SEM images and surface morphology confirmed that nanoparticles were spherical and had smooth surfaces. An MTT assay was conducted in the colon cancer cell lines (CACO2) to evaluate anti-cancerous activity of SM. SM loaded ESNPF2 showed a high potential against colon cancer cells. The overall results suggest that SM loaded ES100-nanoparticels could be a potential option for colon targeting.


  • Open Access

    Development and Evaluation of Nanoformulations Containing Timur Oil and Rosemary Oil for Treatment of Topical Fungal Infections

    by Afeefa Noor, Shahid Jamil, Tariq Waece Sadeq, Muath Sheet Mohammed Ameen, Kanchan Kohli

    The pervasiveness of fungal infections is an issue for skin health globally, and there are a reported 40 million cases in developed and developing countries. Novel drug delivery systems provide better therapeutic efficacy over conventional drug therapy due to their lower side effects and toxicity. Furthermore, combinations of essential oils can represent alternative therapies for fungal infections that are resistant to synthetic drugs. This study is aimed at developing Timur oil into a nanoemulgel and evaluating its antifungal effects. The development of the formulation involved the preparation of a nanoemulsion by the titration method, followed by its evaluation for various physicochemical properties. The antifungal activity of the nanoemulgel against Candida albicans was evaluated. The zone of inhibition was determined using the disk diffusion method. The results show that the developed nanoemulgel has a particle size of 139 ± 6.11 nm, a PDI of 0.309, and a zeta potential of −19.12 ± 2.73 mV. An in vitro drug release study showed a sustained release of 70 ± 0.289% of the drug over a period of 24 h. The % drug permeation across the skin was found to be 79.11 ± 0.319% over 24 h. However, the amount of drug retained in the skin was 56.45 µg/g. The flux for the nanoemulgel was found to be 94.947 µg/cm2/h, indicating a better permeability profile. The nanoemulgel formulation showed a zone of inhibition of 15 ± 2.45 mm, whereas the 1% ketoconazole cream (marketed preparation) exhibited a zone of inhibition of 13 ± 2.13 mm. The results of this study suggest that developed nanoemulgel containing Timur oil and rosemary oil has the potential to be used for treating topical fungal infections caused by Candida albicans.


  • Open Access

    Management Infertility by Hormones Replacement Therapy in Women with Polycystic Ovarian Syndrome

    by Sardar Q. Umer, Tariq W. Sadeq

    Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances; the clinical presentation dominated by manifestations of hyperandrogenism, which generates short- and long-term consequences on female health sterility, infertility is one of the most alarming associated morbidities. Forty women (28.9 ± 0.8 years old) with polycystic ovarian syndrome had infertility and there were enrolled in these clinical trials and randomly allocated into two groups. Group one and Group two were given treated infertility drugs (Clomid 5 mg for 5 days) and recombinant follicle-stimulating hormone (rFSH) 75 IU for long and short duration to get pregnant. Serum testosterone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) of both groups were measured when women diagnosed as PCOS. The results showed that women which treated by low-dose recombinant FSH 75 IU for 3 days consequently (Group one) have significant decreased LH, while progesterone and FSH significantly increased after treated by hormone therapy P ≥ 0.05 while after treatment with recombinant FSH IU for 5 days (Group two), the result showed non-significant effect as compared with the first group. Concluded: Increase pregnant rate and decrease over stimulation syndrome among infertile women associated with polycystic overian syndrome, when treated with applicated low dose and short term by rFSH hormone.